Literature DB >> 24003250

Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Anna L Blobaum1, Thomas M Bridges, Frank W Byers, Mark L Turlington, Margrith E Mattmann, Ryan D Morrison, Claire Mackie, Hilde Lavreysen, José M Bartolomé, Gregor J Macdonald, Thomas Steckler, Carrie K Jones, Colleen M Niswender, P Jeffrey Conn, Craig W Lindsley, Shaun R Stauffer, J Scott Daniels.   

Abstract

Allosteric modulation of G protein-coupled receptors has gained considerable attention in the drug discovery arena because it opens avenues to achieve greater selectivity over orthosteric ligands. We recently identified a series of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu(5)) for the treatment of schizophrenia that exhibited robust heterotropic activation of CYP3A4 enzymatic activity. The prototypical compound from this series, 5-(4-fluorobenzyl)-2-((3-fluorophenoxy)methyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (VU0448187), was found to activate CYP3A4 to >100% of its baseline intrinsic midazolam (MDZ) hydroxylase activity in vitro; activation was CYP3A substrate specific and mGlu(5) PAM dependent. Additional studies revealed the concentration-dependence of CYP3A activation by VU0448187 in multispecies hepatic and intestinal microsomes and hepatocytes, as well as a diminished effect observed in the presence of ketoconazole. Kinetic analyses of the effect of VU0448187 on MDZ metabolism in recombinant P450 or human liver microsomes resulted in a significant increase in V(max) (minimal change in K(m)) and required the presence of cytochrome b5. The atypical kinetics translated in vivo, as rats receiving an intraperitoneal administration of VU0448187 prior to MDZ treatment demonstrated a significant increase in circulating 1- and 4-hydroxy- midazolam (1-OH-MDZ, 4-OH-MDZ) levels compared with rats administered MDZ alone. The discovery of a potent substrate-selective activator of rodent CYP3A with an in vitro to in vivo translation serves to illuminate the impact of increasing intrinsic enzymatic activity of hepatic and extrahepatic CYP3A in rodents, and presents the basis to build models capable of framing the clinical relevance of substrate-dependent heterotropic activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24003250      PMCID: PMC3834130          DOI: 10.1124/dmd.113.052662

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  54 in total

Review 1.  Atypical kinetic profiles in drug metabolism reactions.

Authors:  J Matthew Hutzler; Timothy S Tracy
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

2.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

3.  In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.

Authors:  J Fang; G McKay; J Song; A Remillrd; X Li; K Midha
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

4.  Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.

Authors:  J M Hutzler; R F Frye; K R Korzekwa; R A Branch; S M Huang; T S Tracy
Journal:  Eur J Pharm Sci       Date:  2001-08       Impact factor: 4.384

5.  Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.

Authors:  Amit S Kalgutkar; Timothy J Taylor; Karthik Venkatakrishnan; Emre M Isin
Journal:  Drug Metab Dispos       Date:  2003-03       Impact factor: 3.922

6.  Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation.

Authors:  Kishore K Khan; You Qun He; Tammy L Domanski; James R Halpert
Journal:  Mol Pharmacol       Date:  2002-03       Impact factor: 4.436

7.  Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone.

Authors:  Pamela A Williams; Jose Cosme; Dijana Matak Vinkovic; Alison Ward; Hayley C Angove; Philip J Day; Clemens Vonrhein; Ian J Tickle; Harren Jhoti
Journal:  Science       Date:  2004-07-15       Impact factor: 47.728

Review 8.  Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia.

Authors:  Bita Moghaddam
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

9.  In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.

Authors:  Tsutomu Kotegawa; Bart E Laurijssens; Lisa L Von Moltke; Monette M Cotreau; Michael D Perloff; Karthik Venkatakrishnan; Jill S Warrington; Brian W Granda; Jerold S Harmatz; David J Greenblatt
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

10.  The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution.

Authors:  Jason K Yano; Michael R Wester; Guillaume A Schoch; Keith J Griffin; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2004-07-16       Impact factor: 5.157

View more
  8 in total

1.  Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.

Authors:  Susana Conde-Ceide; Carlos M Martínez-Viturro; Jesús Alcázar; Pedro M Garcia-Barrantes; Hilde Lavreysen; Claire Mackie; Paige N Vinson; Jerri M Rook; Thomas M Bridges; J Scott Daniels; Anton Megens; Xavier Langlois; Wilhelmus H Drinkenburg; Abdellah Ahnaou; Colleen M Niswender; Carrie K Jones; Gregor J Macdonald; Thomas Steckler; P Jeffrey Conn; Shaun R Stauffer; José Manuel Bartolomé-Nebreda; Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2015-05-20       Impact factor: 4.345

2.  Correction to "Allosteric Interactions in Human Cytochrome P450 CYP3A4: The Role of Phenylalanine 213".

Authors:  Ilia G Denisov; Yelena V Grinkova; Prithviraj Nandigrami; Mrinal Shekhar; Emad Tajkhorshid; Stephen G Sligar
Journal:  Biochemistry       Date:  2019-06-06       Impact factor: 3.162

3.  Allosteric Interactions in Human Cytochrome P450 CYP3A4: The Role of Phenylalanine 213.

Authors:  Ilia G Denisov; Yelena V Grinkova; Prithviraj Nandigrami; Mrinal Shekhar; Emad Tajkhorshid; Stephen G Sligar
Journal:  Biochemistry       Date:  2019-02-28       Impact factor: 3.162

4.  Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer.

Authors:  Ilia G Denisov; Yelena V Grinkova; Javier L Baylon; Emad Tajkhorshid; Stephen G Sligar
Journal:  Biochemistry       Date:  2015-03-25       Impact factor: 3.162

5.  Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4.

Authors:  Ilia G Denisov; Yelena V Grinkova; Mark A McLean; Tyler Camp; Stephen G Sligar
Journal:  Biomolecules       Date:  2022-06-20

6.  A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.

Authors:  Anna L Blobaum; Frank W Byers; Thomas M Bridges; Charles W Locuson; P Jeffrey Conn; Craig W Lindsley; J Scott Daniels
Journal:  Drug Metab Dispos       Date:  2015-08-11       Impact factor: 3.922

7.  Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.

Authors:  William C Wright; Jude Chenge; Jingheng Wang; Hazel M Girvan; Lei Yang; Sergio C Chai; Andrew D Huber; Jing Wu; Peter O Oladimeji; Andrew W Munro; Taosheng Chen
Journal:  J Med Chem       Date:  2020-01-22       Impact factor: 7.446

8.  Homotropic Cooperativity of Midazolam Metabolism by Cytochrome P450 3A4: Insight from Computational Studies.

Authors:  Junhao Li; Yue Chen; Yun Tang; Weihua Li; Yaoquan Tu
Journal:  J Chem Inf Model       Date:  2021-04-22       Impact factor: 4.956

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.